Clinical trials: AD
Alzheimer's Disease
Effect of REST in the Alzheimer Disease Continuum
The investigators assume that REST gene polymorphism affects REST protein concentration, and REST protein concentration in peripheral blood is related to cognitive function and hippocampus.
- Trial name
- ERADC (NCT03884023)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Dongzhimen Hospital, Beijing
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.
- Trial name
- NCT05667623
- Testing
- 1% OPA-15406 Ointment, 0% OPA-15406 Vehicle
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Otsuka Beijing Research Institute
Atopic Dermatitis (AD)
Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.
A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision.
- Trial name
- NCT07301658
- Testing
- Novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.
- Where
- Spain
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- i+Med S.Coop.
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Clinical Trial to Evaluate the Efficacy and Safety of an Ozonated Oil in Atopic Dermatitis
This clinical trial is designed to evaluate the efficacy, safety, and tolerability of a topical ozonated vegetable oil formulation in paediatric patients with mild-to-moderate atopic dermatitis.
- Trial name
- NCT07744516
- Testing
- ozonated oil, non-ozonated oil
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Laboratorios Ozoaqua
Atopic Dermatitis
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by…
- Trial name
- ADMIRE (NCT05451316)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
- Trial name
- NCT03921411
- Testing
- Nemolizumab
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Dementia, Alzheimer Disease
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.
- Conditions
- Dementia, Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- NCT05418296
- Testing
- A novel digital health device
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- mandy
Atopic Dermatitis (AD)
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT07182864
- Testing
- MH004 0.1% Ointment, MH004 0.3% Ointment, MH004 1.0% Ointment
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Atopic Dermatitis, Atopic Dermatitis (AD)
Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
This randomized, open-label, parallel-group study will compare the efficacy and safety of Crisaborole 2% ointment and Tacrolimus 0.1% ointment in children with mild to moderate atopic dermatitis.
- Trial name
- NCT07162896
- Testing
- Crisaborole 2%, Tacrolimus 0.1%
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Shalamar Institute of Health Sciences
Mild Cognitive Impairment, Neurocardiogenic Syncope
VINCI-AD: An Investigation of Transcutaneous Vagus Nerve Stimulation in Mild Cognitive Impairment.
The VINCI-AD study will investigate the impact of non-invasive vagus nerve stimulation (VNS) on memory in participants with existing mild memory impairment. VNS is a safe, existing treatment, licensed in epilepsy and depression.
- Conditions
- Mild Cognitive Impairment, Neurocardiogenic Syncope, Memory Impairment, Inflammatory Response
- Trial name
- NCT05514756
- Testing
- Active t-VNS, Baseline assessments
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Tallaght University Hospital
Atopic Dermatitis (AD)
Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis
The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis.
- Trial name
- NCT07113366
- Testing
- FAE cream
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Atopic Dermatitis
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Clinical data suggest that treatment with OM-85, by inducing an early contact with bacterial extracts, could modulate the immunity of children with Atopic Dermatitis, and thus play an active role in the treatment of Atopic…
- Trial name
- NCT05222516
- Testing
- Broncho-Vaxom
- Where
- 28 sites in France, Germany and 2 more
- Volunteers
- 63 people
- Sponsor
- OM Pharma SA
Alzheimer Disease
Phase IIa L-serine Trial for eAD
This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for participation in this study will be identified by the Investigator based on their Clinical Dementia Rating score which will be completed as…
- Trial name
- LSPI-2 (NCT03062449)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Aleksandra Stark
Behavioral Symptoms, Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00337571
- Testing
- Aripiprazole
- Where
- 31 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Atopic Dermatitis
Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?
It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards…
- Trial name
- NCT03142139
- Testing
- RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib, RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib, RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
- Volunteers
- 1,027,559 people
- Sponsor
- Bandim Health Project
Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent participants.
- Trial name
- ROCKET-ASTRO (NCT05704738)
- Testing
- Rocatinlimab
- Where
- 246 sites in United States, Belgium and 20 more
- Volunteers
- 532 people
- Sponsor
- Amgen
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Leigh Syndrome (Maternally Inherited, MILS), Leigh Syndrome (AR, AD, XR)
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells
In this project, the investigators are using iPSC lines derived from patients with Leigh syndrome that carry mutations in the mitochondrial (mtDNA) and in the nuclear DNA (nDNA) to reprogram them into neural progenitor cells and…
- Trial name
- cureMILS (NCT06967831)
- Testing
- skin biopsy, generation of iPSCs, blood drawing
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Atopic Dermatitis
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
- Trial name
- ROCKET-Orbit (NCT05633355)
- Testing
- Rocatinlimab
- Where
- 77 sites in United States, Argentina and 7 more
- Volunteers
- 187 people
- Sponsor
- Amgen